摘要目的:分析磷酸甘露糖异构酶-先天性糖基化障碍（MPI-CDG）的临床特征及D-甘露糖治疗后的转归。方法:病例系列研究。分析2014年12月至2024年12月复旦大学附属儿科医院确诊的5例MPI-CDG患儿的临床、实验室检查、影像学检查、基因检测结果及D-甘露糖治疗后的转归。结果:5例患儿起病年龄为0.3~0.4岁，均以腹泻伴低血糖为首发表现，合并矮小症3例、贫血3例、脾脏肿大3例、肝脏肿大4例、转氨酶升高4例及低白蛋白血症4例。肝脏病理显示肝纤维化3例；基因检测发现8个MPI基因变异，其中2个为未报道的变异。经 D-甘露糖治疗所有患儿腹泻及低血糖在1~2周内缓解，贫血改善；例1出现脾脏进行性增大、肝纤维化进展并发生门静脉高压，但其转氨酶和白蛋白水平始终维持正常；而其余4例患儿的转氨酶升高、低白蛋白血症及肝脏影像学表现均获得改善。结论:MPI-CDG多表现为婴儿期腹泻合并低血糖，常伴多系统受累，经D-甘露糖治疗可显著改善其代谢异常及多数器官损伤，但仍需注意密切随访肝脏变化，警惕肝纤维化发生与发展。

abstractsObjective:To analyze the clinical characteristics of mannose phosphate isomerase-congenital disorders of glycosylation (MPI-CDG) and evaluated the outcomes following D-mannose treatment.Methods:This case-series study analyzed clinical manifestations, laboratory findings, imaging results, genetic data, and outcomes after D-mannose therapy in 5 children with MPI-CDG diagnosed at the Children′s Hospital of Fudan University between December 2014 and December 2024.Results:The age of onset ranged from 0.3 to 0.4 years in all 5 children, who initially presented with diarrhea and hypoglycemia. Associated manifestations included short stature (3 cases), anemia (3 cases), splenomegaly (3 cases), hepatomegaly (4 cases), elevated transaminases (4 cases), and hypoalbuminemia (4 cases). Liver pathology revealed hepatic fibrosis in 3 cases. Genetic testing identified 8 variants in the MPI gene, including 2 novel variants. Following D-mannose treatment, diarrhea and hypoglycemia resolved within 1-2 weeks in all children, with concurrent improvement in anemia. Notably except for Patient 1, who developed progressive splenomegaly, worsening hepatic fibrosis, and portal hypertension despite persistently normal transaminase and albumin levels, the other 4 children showed improvement in transaminase levels, resolution of hypoalbuminemia and amelioration of imaging abnormalities.Conclusions:MPI-CDG typically manifests in infancy with diarrhea and hypoglycemia, often accompanied by multi-system involvement. D-mannose treatment significantly improves metabolic abnormalities and most organ damages. However, close surveillance of liver status is warranted due to the risk of hepatic fibrosis progression in some cases.